Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Description

We facilitate the transition to value-based healthcare by evaluating various treatments, medications, processes, and costs, which aids hospitals, life sciences firms, and payers in pinpointing the most effective treatment strategies for optimal patient results. Our CRCA™ P&T platform equips Pharmacy and Therapeutics committees to implement data-driven enhancements in key quality indicators, including metrics like average length of stay (ALOS) and 30-day readmissions. The innovative POP-BUILDER Rx™ solution offers comparative evaluations among chosen cohorts against CRCA’s extensive real-world data index, which encompasses over 140 million longitudinal patient records. Additionally, our drug remittance dashboard provides an in-depth analysis and reporting of drug remittance information across different payer categories, focusing on high-cost medications at the National Drug Code (NDC) level. Furthermore, we assist hospital finance teams in effectively tracking and enhancing service line costs and profitability, productivity, and revenue cycle performance through our insightful analytics, detailed reporting, and the expertise of our Agilum Healthcare Intelligence team. This comprehensive approach ensures that healthcare providers can make informed decisions that positively impact both operational efficiency and patient care.

Description

Rare diseases often lack comprehensive research, resulting in insufficient knowledge about essential elements for an effective drug discovery initiative. Our innovative AI platform, Healnet, addresses these issues by scrutinizing vast amounts of drug and disease data to uncover new connections that may lead to potential treatments. Utilizing cutting-edge technologies throughout the discovery and development process allows us to operate multiple phases simultaneously and on a large scale. The conventional approach of focusing on a single disease, target, and drug is overly simplistic, yet it remains the standard for most pharmaceutical companies. The future of drug discovery is driven by AI, characterized by parallel processes and an absence of rigid hypotheses, fundamentally integrating the three core paradigms of drug discovery into a cohesive strategy. This new paradigm not only enhances efficiency but also fosters creativity in developing solutions for complex health challenges.

API Access

Has API

API Access

Has API

Screenshots View All

Screenshots View All

Integrations

No details available.

Integrations

No details available.

Pricing Details

No price information available.
Free Trial
Free Version

Pricing Details

No price information available.
Free Trial
Free Version

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Vendor Details

Company Name

Agilum

Founded

2005

Country

United States

Website

agilum.com

Vendor Details

Company Name

Healx

Founded

2014

Country

United Kingdom

Website

healx.io/technology/

Product Features

Alternatives

Alternatives

SYNCRASY Reviews

SYNCRASY

MedCloud Depot